To determine whether risk disclosure would affect BP and kidney testing, researchers collaborated with a genomics stakeholder board (consisting of patients, clinicians, advocates, and health system leaders) to conduct the Genetic Testing to Understand and Address Renal Disease Disparities (GUARDD) trial to study the effects of incorporating APOL1 genotype information into primary care management of adults of African ancestry with hypertension. This evidence concerns the gene APOL1 and hypertensive disorder.